

ALKERMES INC  
Form 8-K  
October 30, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15 (d) of the  
Securities Exchange Act of 1934

**Date of Report** **October 29, 2003**  
(Date of earliest event reported)

**ALKERMES, INC.**

(Exact name of Registrant as specified in its charter)

**Pennsylvania**  
(State of incorporation)

**001-14131**  
(Commission file number)

**23-2472830**  
(IRS employer  
identification  
number)

**88 Sidney Street, Cambridge, Massachusetts 02139**  
(Address of principal executive offices, zip code)

**Area Code (617) 494-0171**  
(Telephone number)

---

**TABLE OF CONTENTS**

Item 5. Other Information.

Item 7. Financial Statements and Exhibits.

SIGNATURES

EXHIBIT INDEX

EX-99.1 PRESS RELEASE ISSUED BY ALKERMES, INC.

---

**Table of Contents**

**Item 5. Other Information.**

On October 29, 2003, Alkermes, Inc. announced the U.S. Food and Drug Administration (FDA) approved RISPERDAL® CONSTA [(risperidone) long-acting injection] for the treatment of schizophrenia. A copy of the press release issued by Alkermes on October 29, 2003, is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 7. Financial Statements and Exhibits.**

(c) Exhibits

99.1 Press Release issued by Alkermes, Inc., dated October 29, 2003.

---

**Table of Contents**

SIGNATURES

Pursuant to requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 30, 2003

Alkermes, Inc.

By: /s/ Kathryn Biberstein

---

Kathryn Biberstein  
Vice President and General Counsel

Edgar Filing: ALKERMES INC - Form 8-K

**Table of Contents**

ALKERMES, INC.

CURRENT REPORT ON FROM 8-K

EXHIBIT INDEX

**Exhibit No.**

**Exhibit**

---

99.1	Press Release issued by Alkermes, Inc., dated October 29, 2003.
------	---